• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21597 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment of varicose veins of the lower limbs]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Addendum to commission H20-08]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Endovascular contra open surgical treatment of symptom generating atherosclerotic lesions of the external iliac artery]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endothelial cell count in subjects who underwent laser photorefractive surgery for myopia or keratoplasty for keratoconus]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Endoscopic tri-modal imaging for improved detection of early neoplasia in the gastrointestinal tract]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermoablation of the duodenal mucosa in type 2 diabetes - Addendum to commission H20-04]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermal ablation of the duodenal mucosa in type 2 diabetes - Assessment according to §137h Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic surgery in patients with middle ear conditions]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic spine surgery for disc disease and lumbar spinal stenosis]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic mucosectomy for the treatment of sessile polyps ]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Endoscopic mucosal resection (EMR) and endoscopic mucosal dissection (EMD) in superficial gastrointestinal tumors]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic full-thickness resection of colorectal lesions]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptabilityy]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Endometriosis – Diagnosis, treatment and patient experiences]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial receptivity array in assisted reproduction]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial microbiome test in assisted reproduction]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial cell co-culture in patients receiving assisted reproduction treatments]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endoluminal brachytherapy in the treatment of cancer of the oesophagus]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endobronchial valves in the treatment of diffuse heterogeneous-type pulmonary emphysema]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endobronchial valves in emphysema]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endobronchial valve implantation for emphysema - 2nd Update 2010]
2009     Committee for New Health Technology Assessment (CNHTA) [Endobronchial ultrasound/fine needle aspiration]
2014     Haute Autorite de sante (HAS) [Endobronchial ultrasound-guided transbronchial needle aspiration]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of pathologies accessible by transbronchial needle aspiration requiring anatomopathological diagnosis]
2014     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [EndoBarrier® evaluation device for the treatment of morbid obesity with or without diabetes mellitus type II]
2010     Andalusian Health Technology Assessment Area (AETSA) [Endo-PAT 2000 in the diagnosis of coronary atherosclerosis]
2014     Norwegian Knowledge Centre for the Health Services (NOKC) [End-of-life care - how to find the appropriate level and intensity of medical treatment of seriously ill and dying patients]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Addendum to Commission A18-61]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a SGB V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/metformin - Addendum to Commission A16-13]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin: benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Addendum to Commission A16-12]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Addendum to Commission A18-20]
2013     The Swedish Council on Health Technology Assessment (SBU) [Emergency care for the elderly patients who are in the poorest health]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Embolization or sclerotherapy of pelvic veins in pelvic congestion syndrome]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Embolization of uterine fibroids - Early Warning on New Health Technology]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Embolization in the treatment of uterine myoma]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: addendum to commission A15-61]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) - Benefit assessment according to §35a Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A19-80]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A16-32]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis type IVA) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (new scientific findings)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eliglustat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2014     Haute Autorite de sante (HAS) [Elements to evaluate for managing a patient in outpatient surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrosurgical units in surgery]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Electronic patient record at an osteoporotic outpatient department - a Health Technology Assessment]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Electronic patient record at an osteoporotic outpatient department - a health technology assessment]
2011     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Electronic Clinical Guides: breast cancer]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic Navigation Bronchoscopy: Use in Dying for Lung Nodules Resection. Horizon Scanning Technologies]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrical stimulation devices to treat delayed unions and pseudarthrosis]
2012     Haute Autorite de sante (HAS) [Elbow joint implants]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elbasvir/grazoprevir (chronic hepatitis C): Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elbasvir/grazoprevir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eladocagene Exuparvovec (aromatic L-amino acid decarboxylase deficiency, = 18 months) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [ELA2 gene point mutation analysis]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eftrenonacog alfa (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eftrenonacog alfa - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efmoroctocog alfa - Benefit assessment according to § 35a Social Code Book V]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (myasthenia gravis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficiency, effectiveness and safety of mechanical ventricular assistance with HeartWare® device in terminal heart failure]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficiency, effectiveness and safety of mechanical ventricular assistance with HeartWare® device in terminal heart failure]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Efficiency of the induction of personalised psychiatric rehabilitation through assessment of, and continuous feedback on, needs and outcomes - a catchment area observational trial]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficiency of the "housing first" approach for people who are homeless and living with mental illness or with disorders associated to psychoactive substances]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficiency of short-term social and psychological therapies: Systematic review]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Efficiency of physiotherapeutic care in Parkinson's disease]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficiency of peritoneal dialysis versus hemodialysis for the treatment of renal insufficiency]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficiency of 3D reconstruction in maxillofacial surgery]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Efficiency in the use of operating surgical blocks. Definition of indicators]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy, safety, and usefulness of genistein in patients with Sanfilippo syndrome]